University of Dundee
Anil Mehta is a Clinical Reader undertaking biochemical and epidemiological research into the children’s disease cystic fibrosis (CF) with 50% time as a consultant paediatrician. His lab-based pharmacology lies at the interface between the biochemistry and physiology of epithelial barrier function. His focus is on novel drug development, analysis of health outcomes and wider rare disease policy for better informed policy making by the EU. The latter is a priority for the EU through their Rare Disease Directive that will require the NHS to plan care for all rare disease patients, where he is a tutor to the EU’s Rare Diseases Organisation - EURORDIS.
Therapies for childhood,Rare Diseases